Keywords: valeant, buys, dow, pharma, 285m, pharmaceuticals, agreed
Valeant buys Dow Pharma for $285M
Article | 15 December 2008
Valeant Pharmaceuticals has agreed to pay $285.0 million to acquire fellow USA-based Dow Pharmaceutical Sciences, a privately-held dermatology company that develops ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Italy's pharma market slump set to continue, warns GlobalData
- Pfizer to split-off remaining 80% interest in Zoetis
